Quick Answer
Envoy Medical, Inc. reported Total Revenue of $241.0 thousand for fiscal year 2025.
Envoy Medical, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $241.0K +7.1% |
$225.0K -28.8% |
$316.0K +33.3% |
$237.0K | — | — |
| Net Income | -$23.76M -14.2% |
-$20.80M +30.5% |
-$29.92M -87.9% |
-$15.92M -6227.9% |
-$251.6K -35796.3% |
-$701.00 |
| Diluted EPS | -$1.23 +17.4% |
-$1.49 +41.3% |
-$2.54 -61.8% |
-$1.57 | — | — |
| Total Assets | $8.56M -25.8% |
$11.54M +39.5% |
$8.27M +223.6% |
$2.56M -99.4% |
$426.90M +355676.7% |
$120.0K |
| Cash and Equivalents | — | — | $4.22M +2204.9% |
$183.0K +22.1% |
$149.8K +499.4% |
$25.0K |
| Stockholders Equity | -$12.16M +35.5% |
-$18.84M -960.9% |
-$1.78M +95.1% |
-$36.20M +19.5% |
-$44.96M -185128.2% |
$24.3K |
| R&D Expense | $12.49M +22.7% |
$10.18M +13.7% |
$8.96M +80.0% |
$4.97M | — | — |
| Operating Income | -$22.27M -15.7% |
-$19.26M -4.9% |
-$18.36M -110.9% |
-$8.71M -67.3% |
-$5.20M -742406.4% |
-$701.00 |
| Shares Outstanding | — | — | 19.55M | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $42.0K | -25.0% | -46.2% |
| Net Income | September 30, 2025 | -$6.48M | -8.8% | -13.9% |
| Diluted EPS | September 30, 2025 | -$0.35 | +10.3% | -9.4% |
| Total Assets | September 30, 2025 | $8.18M | -12.9% | -17.4% |
| Cash and Equivalents | September 30, 2023 | $7.44M | +2363.6% | +5503.5% |
| Stockholders Equity | September 30, 2025 | -$7.66M | +58.7% | +74.3% |
| R&D Expense | September 30, 2025 | $2.70M | -2.1% | +8.7% |
| Operating Income | September 30, 2025 | -$5.71M | -14.8% | -12.6% |
| Shares Outstanding | June 30, 2025 | 21.52M | +15.7% | +0.9% |
- Envoy Medical, Inc. reported Total Revenue of $241.0 thousand for fiscal year 2025.
- Envoy Medical, Inc. showed an increase of +7.1% in Total Revenue compared to the prior fiscal year.
- Envoy Medical, Inc. reported Net Income of -$23.76 million for fiscal year 2025.
- Envoy Medical, Inc. showed a decrease of -14.2% in Net Income compared to the prior fiscal year.
- Envoy Medical, Inc. reported Diluted EPS of $1.23 per share (loss) for fiscal year 2025.
- Envoy Medical, Inc. showed an increase of +17.4% in Diluted EPS compared to the prior fiscal year.
- Envoy Medical, Inc. reported Total Assets of $8.56 million for fiscal year 2025.
- Envoy Medical, Inc. showed a decrease of -25.8% in Total Assets compared to the prior fiscal year.
- Envoy Medical, Inc. reported Cash and Equivalents of $4.22 million for fiscal year 2023.
- Envoy Medical, Inc. showed an increase of +2204.9% in Cash and Equivalents compared to the prior fiscal year.
- Envoy Medical, Inc. reported Stockholders Equity of -$12.16 million for fiscal year 2025.
- Envoy Medical, Inc. showed an increase of +35.5% in Stockholders Equity compared to the prior fiscal year.
- Envoy Medical, Inc. reported R&D Expense of $12.49 million for fiscal year 2025.
- Envoy Medical, Inc. showed an increase of +22.7% in R&D Expense compared to the prior fiscal year.
- Envoy Medical, Inc. reported Operating Income of -$22.27 million for fiscal year 2025.
- Envoy Medical, Inc. showed a decrease of -15.7% in Operating Income compared to the prior fiscal year.
- Envoy Medical, Inc. reported Shares Outstanding of 19.55 million shares for fiscal year 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: